Select therapeutic use:
Indications for Timolol Maleate:
Adults and Children:
<2yrs: not established. ≥2yrs: Initially 1 drop of 0.25% twice daily; max 1 drop of 0.5% twice daily. Transfer from other drugs, see full labeling.
Greater than 1st-degree AV block. Uncompensated cardiac failure. Cardiogenic shock. Sinus bradycardia. History of bronchospasm. Bronchial asthma. Severe COPD. As sole agent in narrow-angle glaucoma. All contact lenses (Timoptic-XE); soft contact lenses (Timoptic and Timoptic-XE).
Poor cardiac reserve should be controlled with digitalis and diuretics. Diabetes. Presbyopia. May mask hypoglycemia or thyrotoxicosis. Myasthenia gravis. Cerebrovascular insufficiency. Measure intraocular pressure after 4 weeks of treatment. Avoid abrupt cessation. Discontinue at 1st sign of cardiac failure and before surgery. Pregnancy (Cat.C). Nursing mothers: not recommended.
May potentiate systemic β-blockers, reserpine, hypoglycemics and mydriatic effect of topical epinephrine. Additive cardiac and pulmonary effects with anticholinesterase miotics. May antagonize bronchodilation from β-adrenergic agonists. May cause conduction defects with calcium channel blockers, digoxin.
Ocular irritation, sensitization, rash, dizziness, blurred vision, corneal anesthesia, headache, GI upset, paresthesias. Systemic β-blocker effects (bradycardia, arrhythmias, hypotension, bronchospasm, heart failure). Aphakic maculopathy (rare).
Formerly known under the brand name Timoptic.
Soln—contact supplier; Ocudose—60; XE—2.5mL, 5mL